Henry J. Kaiser Family Foundation President and CEO Drew Altman dissects the outcomes of last week's midterm elections, including votes to expand Medicaid coverage.
HHS Secretary Alex Azar said the Trump administration is reversing course on voluntary payment models and said more mandatory ones are in the works, including one for cancer care.
HHS' Office of Inspector General found hospitals fraudulently either double counted the number of interns and residents they had or claimed some working at other hospitals to get more graduate medical education funds.
The new political action committee organized to promote a single-payer healthcare platform endorsed fewer than 10 Democratic House candidates.
Healthcare is top of mind for many 2018 midterm voters. In addition to picking lawmakers who will shape federal policy, many states have Medicaid expansion, provider pay provisions and other measures on their ballots.
In a sweeping outpatient payment rule, the CMS will reduce Medicare pay for checkups in outpatient departments by 60% over two years and expand a controversial 340B cut to additional sites of care.
A federal judge ordered HHS to eliminate its Medicare appeals backlog by 2022, giving them nearly two more years to catch up. The judge refused to reduce hospitals' interest rates on outstanding appealed claims.
The CMS wants to make a few dramatic changes to the way it audits Medicare Advantage plans for overpayments. That could leave insurers on the hook for billions of dollars.
Hospitals called on HHS to relax anti-kickback rules that could affect alternative pay models, saying payments between providers in the models shouldn't violate the regulations.
Home healthcare programs are proliferating as health plans and at-risk providers look for ways to keep patients out of the hospital or from returning after being discharged.
Trump's Medicare Part B drug cost plan could move forward, particularly if Democrats win control of the House.
The Trump administration's latest step to tackle high drug prices has generated praise, criticism and a lot of questions from providers, payers and drugmakers. Modern Healthcare runs down five of the top questions.